Angiogenic Growth Factors for Coronary Artery Disease: Current Status and Prospects

J Cardiovasc Pharmacol Ther. 2018 Mar;23(2):130-141. doi: 10.1177/1074248417735399. Epub 2017 Oct 12.

Abstract

Although there have been advances in coronary artery bypass grafting and percutaneous coronary intervention, some patients who have ischemic coronary artery disease (CAD) are ineligible for revascularization due to suboptimal anatomy. Cardiac angiogenesis is not only a physiological response to ischemia or hypoxia but also a potential target of therapeutic strategies. Preclinical studies have shown a great enthusiasm on therapeutic angiogenesis for ischemic CAD. However, the latest trials provided the limited evidence on its efficacy. This article aims to discuss the physiological process of angiogenesis, the characteristic of angiogenic growth factors, delivery system, and clinical and preclinical studies, which can provide a novel insight into the therapeutic angiogenesis for CAD.

Keywords: angiogenesis; angiogenic growth factors; coronary artery disease; therapeutic angiogenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inducing Agents / adverse effects
  • Angiogenesis Inducing Agents / therapeutic use*
  • Angiogenic Proteins / biosynthesis
  • Angiogenic Proteins / genetics
  • Angiogenic Proteins / therapeutic use*
  • Animals
  • Coronary Artery Disease / genetics
  • Coronary Artery Disease / metabolism
  • Coronary Artery Disease / physiopathology
  • Coronary Artery Disease / therapy*
  • Coronary Vessels / drug effects*
  • Coronary Vessels / physiopathology
  • Genetic Therapy / adverse effects
  • Genetic Therapy / methods
  • Humans
  • Neovascularization, Physiologic / drug effects*
  • Neovascularization, Physiologic / genetics
  • Treatment Outcome

Substances

  • Angiogenesis Inducing Agents
  • Angiogenic Proteins